KR20140048857A - 카텝신 c 억제제 - Google Patents

카텝신 c 억제제 Download PDF

Info

Publication number
KR20140048857A
KR20140048857A KR1020137023618A KR20137023618A KR20140048857A KR 20140048857 A KR20140048857 A KR 20140048857A KR 1020137023618 A KR1020137023618 A KR 1020137023618A KR 20137023618 A KR20137023618 A KR 20137023618A KR 20140048857 A KR20140048857 A KR 20140048857A
Authority
KR
South Korea
Prior art keywords
alkyl
aryl
heteroaryl
cycloalkyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020137023618A
Other languages
English (en)
Korean (ko)
Inventor
크리스토퍼 이. 네이프
마이클 알. 팔로비치
Original Assignee
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46638952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20140048857(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 filed Critical 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드
Publication of KR20140048857A publication Critical patent/KR20140048857A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020137023618A 2011-02-11 2012-02-09 카텝신 c 억제제 Ceased KR20140048857A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161441840P 2011-02-11 2011-02-11
US61/441,840 2011-02-11
PCT/US2012/024428 WO2012109415A1 (en) 2011-02-11 2012-02-09 Cathepsin c inhibitors

Publications (1)

Publication Number Publication Date
KR20140048857A true KR20140048857A (ko) 2014-04-24

Family

ID=46638952

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137023618A Ceased KR20140048857A (ko) 2011-02-11 2012-02-09 카텝신 c 억제제

Country Status (24)

Country Link
US (2) US8841463B2 (enExample)
EP (1) EP2672821B9 (enExample)
JP (1) JP5931929B2 (enExample)
KR (1) KR20140048857A (enExample)
CN (1) CN103491777B (enExample)
AR (1) AR085163A1 (enExample)
AU (1) AU2012214405B2 (enExample)
BR (1) BR112013020510A2 (enExample)
CA (1) CA2827157A1 (enExample)
CL (1) CL2013002325A1 (enExample)
CO (1) CO6741219A2 (enExample)
DO (1) DOP2013000182A (enExample)
EA (1) EA023168B1 (enExample)
ES (1) ES2583091T3 (enExample)
IL (1) IL227814A0 (enExample)
MA (1) MA34961B1 (enExample)
MX (1) MX2013009279A (enExample)
PE (1) PE20140999A1 (enExample)
PH (1) PH12013501665A1 (enExample)
SG (1) SG192669A1 (enExample)
TW (1) TW201302736A (enExample)
UY (1) UY33905A (enExample)
WO (1) WO2012109415A1 (enExample)
ZA (1) ZA201306074B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014091443A1 (en) 2012-12-13 2014-06-19 Glaxo Group Limited Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
NO2699580T3 (enExample) 2014-01-24 2018-02-24
CA3013850C (en) * 2016-02-12 2024-01-30 Pharmaxis Ltd. Haloallylamine indole and azaindole derivative inhibitors of lysyl oxidases and uses thereof
AU2023296161A1 (en) 2022-06-13 2025-01-02 Alivexis, Inc. Azacycloalkyl carbonyl cyclic amine compound

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2622581B1 (fr) * 1987-11-03 1990-02-16 Inorgan Sa Rech Develop Pharm Nouveaux derives de l-proline, leur preparation et leurs applications biologiques
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
CN1240355A (zh) * 1996-05-01 2000-01-05 伊莱利利公司 蛋白激酶c抑制剂增强溶癌剂和放射治疗的临床功效的用途
US6214799B1 (en) 1996-05-14 2001-04-10 Agouron Pharmaceuticals, Inc. Antipicornaviral compounds and methods for their use and preparation
US20020107266A1 (en) 2000-12-12 2002-08-08 Marguerita Lim-Wilby Compounds, compositions and methods for treatment of parasitic infections
EP2195321B1 (en) * 2007-04-12 2016-10-19 Pfizer Inc. 3-amido-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives as inhibitors of protein kinase c
BRPI1015540A2 (pt) * 2009-05-07 2019-09-24 Astrazeneca Ab ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
UY32827A (es) * 2009-08-12 2011-02-28 Glaxo Group Ltd Inhibidores de catepsina c
WO2012119941A1 (en) 2011-03-04 2012-09-13 Prozymex A/S Peptidyl nitrilcompounds as peptidase inhibitors

Also Published As

Publication number Publication date
EP2672821B1 (en) 2016-04-20
DOP2013000182A (es) 2014-03-16
ZA201306074B (en) 2014-04-30
AU2012214405B2 (en) 2015-07-23
NZ614540A (en) 2015-03-27
TW201302736A (zh) 2013-01-16
WO2012109415A1 (en) 2012-08-16
SG192669A1 (en) 2013-09-30
EP2672821A4 (en) 2014-08-06
US8841463B2 (en) 2014-09-23
IL227814A0 (en) 2013-09-30
EA201391155A1 (ru) 2014-01-30
ES2583091T3 (es) 2016-09-19
JP2014506577A (ja) 2014-03-17
EP2672821B9 (en) 2016-11-23
PH12013501665A1 (en) 2019-07-17
AR085163A1 (es) 2013-09-11
MA34961B1 (fr) 2014-03-01
US20130324584A1 (en) 2013-12-05
MX2013009279A (es) 2013-10-28
CL2013002325A1 (es) 2014-01-03
US9187461B2 (en) 2015-11-17
EP2672821A1 (en) 2013-12-18
BR112013020510A2 (pt) 2016-07-12
UY33905A (es) 2012-08-31
CN103491777B (zh) 2015-05-06
AU2012214405A1 (en) 2013-04-18
US20140364476A1 (en) 2014-12-11
EA023168B1 (ru) 2016-04-29
PE20140999A1 (es) 2014-09-11
CN103491777A (zh) 2014-01-01
CA2827157A1 (en) 2012-08-16
CO6741219A2 (es) 2013-08-30
JP5931929B2 (ja) 2016-06-08

Similar Documents

Publication Publication Date Title
JP7721561B2 (ja) ノロウイルス及びコロナウイルス複製の阻害剤
KR101991327B1 (ko) 오피오이드 수용체 리간드와 그 용도 및 제조방법
ES2560612T7 (es) Derivados bencilamina como inhibidores de la calicreina plasmática
EA021755B1 (ru) ПИРАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ENaC БЛОКАТОРОВ
EA009941B1 (ru) Имидазопиридинзамещённые тропановые производные, обладающие активностью антагониста ccr5 рецептора, для лечения вируса иммунодефицита человека (вич) и воспаления
US20110230505A1 (en) Quinazoline inhibitors of bace 1 and methods of using
WO2014091443A1 (en) Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
US20230234954A1 (en) Compound used as ret kinase inhibitor and application thereof
US9187461B2 (en) Cathepsin C inhibitors
JP6479749B2 (ja) トロンビン阻害剤としてのハロゲノピラゾール
CZ20022096A3 (cs) Kvarterní amoniová sloučenina pro použití při léčení a/nebo prevenci kašle u teplokrevného živočicha a farmaceutický prostředek ji obsahující
WO2011025799A1 (en) Cathepsin c inhibitors
KR20120061870A (ko) 카텝신 ｃ 억제제
EP4486720A1 (en) Aryl alkynamide derivatives
WO2013161980A1 (ja) シクロヘキサンジアミド誘導体及びその医薬用途
WO2012112733A1 (en) Cathepsin c inhibitors
NZ614540B2 (en) Cathepsin c inhibitors
US20230122967A1 (en) Novel compounds as inhibitors of pcsk9
WO2015046404A1 (ja) 肺高血圧症の治療剤又は予防剤
WO2024051795A1 (zh) 用作泛素-特异性蛋白酶抑制剂的取代嘌呤酮衍生物
EA045146B1 (ru) Гетероароматические соединения в качестве ингибиторов ванина
TW200302724A (en) Piperiding derivative compound and pharmaceuticals containing same as active ingredient
CZ20022097A3 (cs) Způsob pro léčení a/nebo prevenci kaąle v teplokrevném ľivočichu, pouľití, sloučenina a farmaceutický prostředek

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130906

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170116

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180122

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180528

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180122

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I